Xu, J. et al. National Vital Statistics Reports, Volume 70, Number 8 July 26, 2016. Deaths: final data 2019. Natl. Vital Stat. Rep. 70, (2021).
Hirode, G. & Wong, R. J. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA 323, 2526â2528 (2020).
Google ScholarÂ
Liang, X. et al. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011â18. Postgrad. Med. J. 99, 985â992 (2023).
Google ScholarÂ
Choudhuri, S. & Klaassen, C. D. Molecular regulation of bile acid homeostasis. Drug Metab. Dispos. 50, 425â455 (2022).
Google ScholarÂ
Chiang, J. Y. L. Bile acid metabolism and signaling. Compr. Physiol. 3, 1191â1212 (2013).
Google ScholarÂ
Yang, Y. & Zhang, J. Bile acid metabolism and circadian rhythms. Am. J. Physiol. Gastrointest. Liver Physiol. 319, G549âG563 (2020).
Google ScholarÂ
May 19, 2023: Meeting of the Gastrointestinal Drugs Advisory Committee Meeting Announcement – 05/19/2023. https://www.fda.gov/advisory-committees/committees-and-meeting-materials/may-19-2023-meeting-gastrointestinal-drugs-advisory-committee-meeting-announcement-05192023#event-materials (FDA, 2023).
Thomas, C. et al. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678â693 (2008).
Google ScholarÂ
Perino, A., Demagny, H., Velazquez-Villegas, L. & Schoonjans, K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol. Rev. 101, 683â731 (2021).
Google ScholarÂ
Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137â174 (2003).
Google ScholarÂ
Yetti, H. et al. Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet. PLOS One. 13, e0192863 (2018).
Google ScholarÂ
Lake, A. D. et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol. Appl. Pharmacol. 268, 132â140 (2013).
Google ScholarÂ
Worthmann, A. et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat. Med. 23, 839â849 (2017).
Google ScholarÂ
Ishibashi, S. et al. Disruption of cholesterol 7α-hydroxylase gene in mice. J. Biol. Chem. 271, 18017â18023 (1996).
Google ScholarÂ
Ferdinandusse, S. & Houten, S. M. Peroxisomes and bile acid biosynthesis. Biochim. Biophys. Acta BBA Mol. Cell Res. 1763, 1427â1440 (2006).
Google ScholarÂ
Li, J. & Dawson, P. A. Animal models to study bile acid metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 895â911 (2019).
Google ScholarÂ
Alnouti, Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol. Sci. 108, 225â246 (2009).
Google ScholarÂ
Trottier, J. et al. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants and response to fenofibrate. Clin. Pharmacol. Ther. 94, 533â543 (2013).
Google ScholarÂ
Chiang, J. Y. Recent advances in understanding bile acid homeostasis. F1000Research. 6, 2029 (2017).
Google ScholarÂ
Botham, K. M. & Boyd, G. S. The metabolism of chenodeoxycholic acid to beta-muricholic acid in rat liver. Eur. J. Biochem. 134, 191â196 (1983).
Google ScholarÂ
Sacquet, E. et al. Intestinal absorption, excretion, and biotransformation of hyodeoxycholic acid in man. J. Lipid Res. 24, 604â613 (1983).
Google ScholarÂ
de Boer, J. F. et al. A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice [S]. J. Lipid Res. 61, 291â305 (2020).
Google ScholarÂ
Xie, Y. et al. Gamma-muricholic acid inhibits nonalcoholic steatohepatitis: abolishment of steatosis-dependent peroxidative impairment by FXR/SHP/LXRα/FASN signaling. Nutrients 15, 1255 (2023).
Google ScholarÂ
Di Ciaula, A. et al. Bile acid physiology. Ann. Hepatol. 16, S4âS14 (2017).
Google ScholarÂ
Honda, A. et al. Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J. Lipid Res. 61, 54â69 (2020).
Google ScholarÂ
Wahlström, A., Sayin, S. I., Marschall, H.-U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41â50 (2016).
Google ScholarÂ
Tanaka, H., Hashiba, H., Kok, J. & Mierau, I. Bile salt hydrolase of Bifidobacterium longum-biochemical and genetic characterization. Appl. Environ. Microbiol. 66, 2502â2512 (2000).
Google ScholarÂ
Guzior, D. V. & Quinn, R. A. Review: microbial transformations of human bile acids. Microbiome 9, 140 (2021).
Google ScholarÂ
Ridlon, J. M., Kang, D.-J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241â259 (2006).
Google ScholarÂ
Foley, M. H. et al. Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut. Nat. Microbiol. 8, 611â628 (2023).
Google ScholarÂ
Kim, G.-B., Yi, S.-H. & Lee, B. H. Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains. J. Dairy Sci. 87, 258â266 (2004).
Google ScholarÂ
Elkins, C. A., Moser, S. A. & Savage, D. C. Genes encoding bile salt hydrolases and conjugated bile salt transporters in Lactobacillus johnsonii 100-100 and other Lactobacillus species. Microbiology 147, 3403â3412 (2001).
Google ScholarÂ
Corzo, G. & Gilliland, S. E. Bile salt hydrolase activity of three strains of Lactobacillus acidophilus. J. Dairy Sci. 82, 472â480 (1999).
Google ScholarÂ
Coleman, J. P. & Hudson, L. L. Cloning and characterization of a conjugated bile acid hydrolase gene from Clostridium perfringens. Appl. Environ. Microbiol. 61, 2514â2520 (1995).
Google ScholarÂ
Wijaya, A. et al. Cloning of the bile salt hydrolase (bsh) gene from Enterococcus faecium FAIR-E 345 and chromosomal location of bsh genes in food enterococci. J. Food Prot. 67, 2772â2778 (2004).
Google ScholarÂ
Dussurget, O. et al. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol. Microbiol. 45, 1095â1106 (2002).
Google ScholarÂ
Dean, M. et al. Characterization of cholylglycine hydrolase from a bile-adapted strain of Xanthomonas maltophilia and its application for quantitative hydrolysis of conjugated bile salts. Appl. Environ. Microbiol. 68, 3126â3128 (2002).
Google ScholarÂ
Kawamoto, K., Horibe, I. & Uchida, K. Purification and characterization of a new hydrolase for conjugated bile acids, chenodeoxycholyltaurine hydrolase, from Bacteroides vulgatus. J. Biochem. 106, 1049â1053 (1989).
Google ScholarÂ
Delpino, M. V. et al. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect. Immun. 75, 299â305 (2007).
Google ScholarÂ
Joyce, S. A. & Gahan, C. G. M. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig. Dis. Basel Switz. 35, 169â177 (2017).
Google ScholarÂ
Doden, H. et al. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. Appl. Environ. Microbiol. 84, e00235â18 (2018).
Google ScholarÂ
Quinn, R. A. et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579, 123â129 (2020).
Google ScholarÂ
Guzior, D. V. et al. Bile salt hydrolase acyltransferase activity expands bile acid diversity. Nature 626, 852â858 (2024).
Google ScholarÂ
Rimal, B. et al. Bile salt hydrolase catalyses formation of amine-conjugated bile acids. Nature 626, 859â863 (2024).
Google ScholarÂ
van de Waterbeemd, H., Karajiannis, H. & El Tayar, N. Lipophilicity of amino acids. Amino Acids 7, 129â145 (1994).
Google ScholarÂ
Ridlon, J. M. & Hylemon, P. B. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium. J. Lipid Res. 53, 66â76 (2012).
Google ScholarÂ
Mallonee, D. H., Adams, J. L. & Hylemon, P. B. The bile acid-inducible baiB gene from Eubacterium sp. strain VPI 12708 encodes a bile acid-coenzyme A ligase. J. Bacteriol. 174, 2065â2071 (1992).
Google ScholarÂ
Dawson, J. A., Mallonee, D. H., Björkhem, I. & Hylemon, P. B. Expression and characterization of a C24 bile acid 7 alpha-dehydratase from Eubacterium sp. strain VPI 12708 in Escherichia coli. J. Lipid Res. 37, 1258â1267 (1996).
Google ScholarÂ
Coleman, J. P., White, W. B. & Hylemon, P. B. Molecular cloning of bile acid 7-dehydroxylase from Eubacterium sp. strain VPI 12708. J. Bacteriol. 169, 1516â1521 (1987).
Google ScholarÂ
Kang, D.-J. et al. Clostridium scindens baiCD and baiH genes encode stereo-specific 7alpha/7beta-hydroxy-3-oxo-delta4-cholenoic acid oxidoreductases. Biochim. Biophys. Acta 1781, 16â25 (2008).
Google ScholarÂ
Mallonee, D. H. & Hylemon, P. B. Sequencing and expression of a gene encoding a bile acid transporter from Eubacterium sp. strain VPI 12708. J. Bacteriol. 178, 7053â7058 (1996).
Google ScholarÂ
Heinken, A. et al. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome 7, 75 (2019).
Google ScholarÂ
Bhowmik, S. et al. Structure and functional characterization of a bile acid 7α dehydratase BaiE in secondary bile acid synthesis. Proteins 84, 316â331 (2016).
Google ScholarÂ
Ridlon, J. M. et al. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7, 22â39 (2016).
Google ScholarÂ
Funabashi, M. et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582, 566â570 (2020).
Google ScholarÂ
Harris, S. C. et al. Bile acid oxidation by Eggerthella lenta strains C592 and DSM 2243T. Gut Microbes 9, 523â539 (2018).
Google ScholarÂ
Hirano, S. & Masuda, N. Epimerization of the 7-hydroxy group of bile acids by the combination of two kinds of microorganisms with 7 alpha- and 7 beta-hydroxysteroid dehydrogenase activity, respectively. J. Lipid Res. 22, 1060â1068 (1981).
Google ScholarÂ
Eggert, T., Bakonyi, D. & Hummel, W. Enzymatic routes for the synthesis of ursodeoxycholic acid. J. Biotechnol. 191, 11â21 (2014).
Google ScholarÂ
Giovannini, P. P. et al. 7α- and 12α-Hydroxysteroid dehydrogenases from Acinetobacter calcoaceticus lwoffii: a new integrated chemo-enzymatic route to ursodeoxycholic acid. Steroids 73, 1385â1390 (2008).
Google ScholarÂ
Wegner, K. et al. Rapid analysis of bile acids in different biological matrices using LC-ESI-MS/MS for the investigation of bile acid transformation by mammalian gut bacteria. Anal. Bioanal. Chem. 409, 1231â1245 (2017).
Google ScholarÂ
Nouioui, I. et al. Genome-based taxonomic classification of the phylum actinobacteria. Front. Microbiol. 9, (2018).
Mythen, S. M. et al. Targeted synthesis and characterization of a gene cluster encoding NAD(P)H-dependent 3α-, 3β-, and 12α-hydroxysteroid dehydrogenases from Eggerthella CAG:298, a gut metagenomic sequence. Appl. Environ. Microbiol. 84, e02475â17 (2018).
Google ScholarÂ
Lepercq, P. et al. Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by Clostridium baratii isolated from human feces. FEMS Microbiol. Lett. 235, 65â72 (2004).
Google ScholarÂ
Pedrini, P. et al. Xanthomonas maltophilia CBS 897.97 as a source of new 7beta- and 7alpha-hydroxysteroid dehydrogenases and cholylglycine hydrolase: improved biotransformations of bile acids. Steroids 71, 189â198 (2006).
Google ScholarÂ
Lee, J.-Y. et al. Contribution of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon. J. Lipid Res. 54, 3062â3069 (2013).
Google ScholarÂ
Ferrandi, E. E. et al. In search of sustainable chemical processes: cloning, recombinant expression, and functional characterization of the 7α- and 7β-hydroxysteroid dehydrogenases from Clostridium absonum. Appl. Microbiol. Biotechnol. 95, 1221â1233 (2012).
Google ScholarÂ
Liu, L., Aigner, A. & Schmid, R. D. Identification, cloning, heterologous expression, and characterization of a NADPH-dependent 7β-hydroxysteroid dehydrogenase from Collinsella aerofaciens. Appl. Microbiol. Biotechnol. 90, 127â135 (2011).
Google ScholarÂ
Macdonald, I. A., Jellett, J. F., Mahony, D. E. & Holdeman, L. V. Bile salt 3α- and 12α-hydroxysteroid dehydrogenases from eubacterium lentum and related organisms. Appl. Environ. Microbiol. 37, 992â1000 (1979).
Google ScholarÂ
Edenharder, R. & Schneider, J. 12 beta-dehydrogenation of bile acids by Clostridium paraputrificum, C. tertium, and C. difficile and epimerization at carbon-12 of deoxycholic acid by cocultivation with 12 alpha-dehydrogenating Eubacterium lentum. Appl. Environ. Microbiol. 49, 964â968 (1985).
Google ScholarÂ
Heuman, D. M., Hylemon, P. B. & Vlahcevic, Z. R. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J. Lipid Res. 30, 1161â1171 (1989).
Google ScholarÂ
Chiang, J. Y. L. & Ferrell, J. M. Bile acid metabolism in liver pathobiology. Gene Expr. 18, 71â87 (2018).
Google ScholarÂ
Thakare, R. et al. Species differences in bile acids I. Plasma and urine bile acid composition. J. Appl. Toxicol. 38, 1323â1335 (2018).
Google ScholarÂ
Setchell, K. D. R. et al. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency. Gastroenterology 144, 945â955.e6 (2013).
Google ScholarÂ
van de Peppel, I. P., Bodewes, F. A. J. A., Verkade, H. J. & Jonker, J. W. Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. J. Cyst. Fibros. 18, 313â320 (2019).
Google ScholarÂ
Suga, T. et al. Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3. PLoS ONE 12, e0169719 (2017).
Google ScholarÂ
Kullak-Ublick, G. A., Stieger, B., Hagenbuch, B. & Meier, P. J. Hepatic transport of bile salts. Semin. Liver Dis. 20, 273â292 (2000).
Google ScholarÂ
Wang, D. Q.-H., Tazuma, S., Cohen, D. E. & Carey, M. C. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G494âG502 (2003).
Google ScholarÂ
Hofmann, A. F., Hagey, L. R. & Krasowski, M. D. Bile salts of vertebrates: structural variation and possible evolutionary significance. J. Lipid Res. 51, 226â246 (2010).
Google ScholarÂ
Higuchi, S. The physiological importance of bile acid structure and composition on glucose homeostasis. Curr. Diab. Rep. 20, 42 (2020).
Google ScholarÂ
Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362â1365 (1999).
Google ScholarÂ
Wang, H. et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell. 3, 543â553 (1999).
Google ScholarÂ
Lew, J.-L. et al. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. 279, 8856â8861 (2004).
Google ScholarÂ
Li, F. et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4, 2384 (2013).
Google ScholarÂ
Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714â719 (2002).
Google ScholarÂ
Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435â9440 (2003).
Google ScholarÂ
Chevre, R. et al. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. FASEB J. 32, 3792â3802 (2018).
Google ScholarÂ
Mukhopadhyay, S. & Maitra, U. Chemistry and biology of bile acids. Curr. Sci. 87, 1666â1683 (2004).
Google ScholarÂ
Halilbasic, E., Claudel, T. & Trauner, M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155â168 (2013).
Google ScholarÂ
Boyer, J. L. In Comprehensive Physiology (ed. Terjung, R.) 1035â1078 (Wiley, 2013).
Dawson, P. A., Lan, T. & Rao, A. Bile acid transporters. J. Lipid Res. 50, 2340â2357 (2009).
Google ScholarÂ
Shneider, B. L. et al. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J. Clin. Invest. 95, 745â754 (1995).
Google ScholarÂ
Houten, S. & Auwerx, J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36, 482â491 (2004).
Google ScholarÂ
Hofmann, A. F. & Hagey, L. R. Bile Acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65, 2461â2483 (2008).
Google ScholarÂ
Dawson, P. A. et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278, 33920â33927 (2003).
Google ScholarÂ
Rao, A. et al. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc. Natl Acad. Sci. USA 105, 3891â3896 (2008).
Google ScholarÂ
Kemper, J. K. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 1812, 842â850 (2011).
Google ScholarÂ
Jiang, L. et al. Farnesoid X receptor (FXR): structures and ligands. Comput. Struct. Biotechnol. J. 19, 2148â2159 (2021).
Google ScholarÂ
Ramos Pittol, J. M. et al. FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs. Gastroenterology 159, 1853â1865.e10 (2020).
Google ScholarÂ
Cunningham, F. et al. Ensembl 2022. Nucleic Acids Res. 50, D988âD995 (2022).
Google ScholarÂ
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Google ScholarÂ
Torres, J. et al. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm. Bowel Dis. 19, 275â282 (2013).
Google ScholarÂ
Bailey, A. M. et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G48âG58 (2014).
Google ScholarÂ
Selmin, O. I. et al. Inactivation of adenomatous polyposis coli reduces bile acid/farnesoid X receptor expression through Fxr gene CpG methylation in mouse colon tumors and human colon cancer cells. J. Nutr. 146, 236â242 (2016).
Google ScholarÂ
Cabrerizo, R. et al. Promoter DNA methylation of farnesoid X receptor and pregnane X receptor modulates the intrahepatic cholestasis of pregnancy phenotype. PLoS ONE 9, e87697 (2014).
Google ScholarÂ
Wan, Y.-J. Y. & Sheng, L. Regulation of bile acid receptor activity. Liver Res. 2, 180â185 (2018).
Google ScholarÂ
Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392â404 (2009).
Google ScholarÂ
Purushotham, A. et al. Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1α/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol. Cell. Biol. 32, 1226â1236 (2012).
Google ScholarÂ
Yang, F., Hu, Y., Liu, H.-X. & Wan, Y.-J. Y. MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor. J. Biol. Chem. 290, 6507â6515 (2015).
Google ScholarÂ
Xu, D. et al. miR-22 represses cancer progression by inducing cellular senescence. J. Cell Biol. 193, 409â424 (2011).
Google ScholarÂ
Choi, S.-E. et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12, 1062â1072 (2013).
Google ScholarÂ
Balasubramaniyan, N., Luo, Y., Sun, A.-Q. & Suchy, F. J. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J. Biol. Chem. 288, 13850â13862 (2013).
Google ScholarÂ
Zhang, Y., Hagedorn, C. H. & Wang, L. Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta 1812, 893â908 (2011).
Google ScholarÂ
Miao, J. et al. Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol. Cell. Biol. 29, 6170â6181 (2009).
Google ScholarÂ
Kadam, S. & Emerson, B. M. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol. Cell. 11, 377â389 (2003).
Google ScholarÂ
Strobeck, M. W. et al. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J. Biol. Chem. 277, 4782â4789 (2002).
Google ScholarÂ
Smith, Z., Ryerson, D. & Kemper, J. K. Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors. Mol. Cell. Endocrinol. 368, 59â70 (2013).
Google ScholarÂ
Fang, S. et al. Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism. Mol. Cell. Biol. 27, 1407â1424 (2007).
Google ScholarÂ
Goo, Y.-H. et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. Mol. Cell. Biol. 23, 140â149 (2003).
Google ScholarÂ
Lee, J. et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc. Natl Acad. Sci. USA 106, 8513â8518 (2009).
Google ScholarÂ
Lee, S., Roeder, R. G. & Lee, J. W. Roles of histone H3-lysine 4 methyltransferase complexes in NR-mediated gene transcription. Prog. Mol. Biol. Transl. Sci. 87, 343â382 (2009).
Google ScholarÂ
Kim, D.-H., Lee, J., Lee, B. & Lee, J. W. ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Mol. Endocrinol. 23, 1556â1562 (2009).
Google ScholarÂ
Kim, D.-H., Kim, J. & Lee, J. W. Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis. Mol. Endocrinol. 25, 2076â2083 (2011).
Google ScholarÂ
Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217â225 (2005).
Google ScholarÂ
Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
Google ScholarÂ
Zhang, J. H. et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G940âG948 (2013).
Google ScholarÂ
Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol. Metab. 3, 19â28 (2013).
Google ScholarÂ
Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9â15 (2013).
Google ScholarÂ
Byun, S. et al. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Nat. Commun. 9, 2590 (2018).
Google ScholarÂ
Zhang, S. Q. et al. Shp2 regulates Src family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell. 13, 341â355 (2004).
Google ScholarÂ
Li, S. et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab. 20, 320â332 (2014).
Google ScholarÂ
Belov, A. A. & Mohammadi, M. Grb2, a double-edged sword of receptor tyrosine kinase signaling. Sci. Signal. 5, pe49âpe49 (2012).
Google ScholarÂ
Xie, C. et al. An intestinal farnesoid X receptorâceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66, 613â626 (2017).
Google ScholarÂ
Miao, J. et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitinâproteasomal degradation. Genes Dev. 23, 986â996 (2009).
Google ScholarÂ
Somm, E. & Jornayvaz, F. R. Fibroblast growth factor 15/19: from basic functions to therapeutic perspectives. Endocr. Rev. 39, 960â989 (2018).
Google ScholarÂ
Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell. 6, 517â526 (2000).
Google ScholarÂ
Stroup, D. & Chiang, J. Y. HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7alpha-hydroxylase gene (CYP7A1). J. Lipid Res. 41, 1â11 (2000).
Google ScholarÂ
Zhang, M. & Chiang, J. Y. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J. Biol. Chem. 276, 41690â41699 (2001).
Google ScholarÂ
Yang, Y., Zhang, M., Eggertsen, G. & Chiang, J. Y. L. On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. Biochim. Biophys. Acta 1583, 63â73 (2002).
Google ScholarÂ
Yoshida, E. et al. Functional association between CBP and HNF4 in trans-activation. Biochem. Biophys. Res. Commun. 241, 664â669 (1997).
Google ScholarÂ
Cooney, A. J., Tsai, S. Y., OâMalley, B. W. & Tsai, M. J. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors. Mol. Cell. Biol. 12, 4153â4163 (1992).
Google ScholarÂ
Ge, M., Shao, R. & He, H. Advances in understanding the regulatory mechanism of cholesterol 7α-hydroxylase. Biochem. Pharmacol. 164, 152â164 (2019).
Google ScholarÂ
Wang, Y. et al. An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Nat. Commun. 11, 3612 (2020).
Google ScholarÂ
Wan, Z. Y. et al. Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells. Hepatology 64, 1289â1301 (2016).
Google ScholarÂ
Kerr, T. A. et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell. 2, 713â720 (2002).
Google ScholarÂ
Kir, S. et al. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J. Biol. Chem. 287, 41334â41341 (2012).
Google ScholarÂ
Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664â2672 (2007).
Google ScholarÂ
Rizzo, G. et al. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metab. Disord. 5, 289â303 (2005).
Google ScholarÂ
Eloranta, J. J. & Kullak-Ublick, G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433, 397â412 (2005).
Google ScholarÂ
Zollner, G., Marschall, H.-U., Wagner, M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231â251 (2006).
Google ScholarÂ
Watanabe, M. et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408â1418 (2004).
Google ScholarÂ
Yoshikawa, T. et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21, 2991â3000 (2001).
Google ScholarÂ
Kim, Y.-C. et al. Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. Nat. Commun. 11, 5969 (2020).
Google ScholarÂ
Wang, Y., Viscarra, J., Kim, S.-J. & Sul, H. S. Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 16, 678â689 (2015).
Google ScholarÂ
Kast, H. R. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15, 1720â1728 (2001).
Google ScholarÂ
Claudel, T. et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125, 544â555 (2003).
Google ScholarÂ
Hayhurst, G. P. et al. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21, 1393â1403 (2001).
Google ScholarÂ
Pineda Torra, I. et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17, 259â272 (2003).
Google ScholarÂ
Savkur, R. S., Bramlett, K. S., Michael, L. F. & Burris, T. P. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem. Biophys. Res. Commun. 329, 391â396 (2005).
Google ScholarÂ
Hirokane, H. et al. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279, 45685â45692 (2004).
Google ScholarÂ
Claudel, T. et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109, 961â971 (2002).
Google ScholarÂ
Mak, P. A., Kast-Woelbern, H. R., Anisfeld, A. M. & Edwards, P. A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43, 2037â2041 (2002).
Google ScholarÂ
Dong, B. et al. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR. Int. J. Mol. Med. 43, 1927â1938 (2019).
Google ScholarÂ
Zhang, Y. et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J. Biol. Chem. 285, 3035â3043 (2010).
Google ScholarÂ
Xu, Y. et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64, 1072â1085 (2016).
Google ScholarÂ
Jakulj, L. et al. Transintestinal cholesterol transport is active in mice and humans and controls ezetimibe-induced fecal neutral sterol excretion. Cell Metab. 24, 783â794 (2016).
Google ScholarÂ
Yu, L. et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 280, 8742â8747 (2005).
Google ScholarÂ
Al-Dury, S. et al. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. J. Hepatol. 71, 986â991 (2019).
Google ScholarÂ
Langhi, C. et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 582, 949â955 (2008).
Google ScholarÂ
Ghosh Laskar, M., Eriksson, M., Rudling, M. & Angelin, B. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J. Intern. Med. 281, 575â585 (2017).
Google ScholarÂ
Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006â1011 (2006).
Google ScholarÂ
Ma, K., Saha, P. K., Chan, L. & Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102â1109 (2006).
Google ScholarÂ
Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039â11049 (2006).
Google ScholarÂ
Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771â784 (2010).
Google ScholarÂ
Caron, S. et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol. Cell. Biol. 33, 2202â2211 (2013).
Google ScholarÂ
Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621â1624 (2011).
Google ScholarÂ
Yamagata, K. et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279, 23158â23165 (2004).
Google ScholarÂ
Wattanavanitchakorn, S. et al. CCAAT-enhancer binding protein-α (C/EBPα) and hepatocyte nuclear factor 4α (HNF4α) regulate expression of the human fructose-1,6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells. PLoS ONE 13, e0194252 (2018).
Google ScholarÂ
Zhang, X., Yang, S., Chen, J. & Su, Z. Unraveling the regulation of hepatic gluconeogenesis. Front. Endocrinol. 9, 802 (2019).
Google ScholarÂ
Trabelsi, M.-S. et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015).
Google ScholarÂ
Wondisford, A. R. et al. Control of Foxo1 gene expression by co-activator P300. J. Biol. Chem. 289, 4326â4333 (2014).
Google ScholarÂ
Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13, 729â738 (2011).
Google ScholarÂ
Lin, J. et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119, 121â135 (2004).
Google ScholarÂ
Koo, S.-H. et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat. Med. 10, 530â534 (2004).
Google ScholarÂ
Massafra, V. et al. Farnesoid X receptor activation promotes hepatic amino acid catabolism and ammonium clearance in mice. Gastroenterology 152, 1462â1476.e10 (2017).
Google ScholarÂ
Renga, B. et al. The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. Biochim. Biophys. Acta 1812, 1522â1531 (2011).
Google ScholarÂ
Gingras, A.-C., Raught, B. & Sonenberg, N. eIF4 Initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913â963 (1999).
Google ScholarÂ
Schote, A. B., Turner, J. D., Schiltz, J. & Muller, C. P. Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. 44, 1436â1445 (2007).
Google ScholarÂ
Yao, J. et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J. Gastroenterol. 20, 14430â14441 (2014).
Google ScholarÂ
Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475â479 (2020).
Google ScholarÂ
Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. -Heart Circ. Physiol. 296, H272âH281 (2009).
Google ScholarÂ
Vavassori, P. et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251â6261 (2009).
Google ScholarÂ
Hao, H. et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab. 25, 856â867.e5 (2017).
Google ScholarÂ
Wang, Y.-D. et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology 48, 1632â1643 (2008).
Google ScholarÂ
Malhi, H., Guicciardi, M. E. & Gores, G. J. Hepatocyte death: a clear and present danger. Physiol. Rev. 90, 1165â1194 (2010).
Google ScholarÂ
Wang, H. et al. Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis. EBioMedicine 37, 322â333 (2018).
Google ScholarÂ
Gai, Z. et al. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease. Liver Int. 40, 844â859 (2020).
Google ScholarÂ
Bhogal, H. K. & Sanyal, A. J. The molecular pathogenesis of cholestasis in sepsis. Front. Biosci. -Elite 5, 87â96 (2013).
Google ScholarÂ
Adachi, T. et al. The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury. J. Clin. Biochem. Nutr. 54, 129â135 (2014).
Google ScholarÂ
Panzitt, K. & Wagner, M. FXR in liver physiology: multiple faces to regulate liver metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166133 (2021).
Google ScholarÂ
Yin, Z., Pascual, C. & Klionsky, D. J. Autophagy: machinery and regulation. Microb. Cell. 3, 588â596 (2016).
Google ScholarÂ
Seok, S. et al. Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 516, 108â111 (2014).
Google ScholarÂ
Lee, J. M. et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516, 112â115 (2014).
Google ScholarÂ
Ferré, P. & Foufelle, F. A new role for a metabolic star: AMP-activated protein kinase stimulates fat absorption. Cell Metab. 13, 1â2 (2011).
Google ScholarÂ
Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 124, 1037â1051 (2014).
Google ScholarÂ
Guo, C., Chen, W.-D. & Wang, Y.-D. TGR5, not only a metabolic regulator. Front. Physiol. 7, 646 (2016).
Google ScholarÂ
Gao, S. et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 predicts prognosis of acute-on-chronic hepatitis B liver failure. J. Viral Hepat. 22, 112â119 (2015).
Google ScholarÂ
Han, L.-Y. et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int. J. Med. Sci. 11, 164â171 (2014).
Google ScholarÂ
Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J. Biol. Chem. 292, 11055â11069 (2017).
Google ScholarÂ
Wang, X. X. et al. G Protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes. J. Am. Soc. Nephrol. 27, 1362â1378 (2016).
Google ScholarÂ
Rajagopal, S. et al. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G527âG535 (2013).
Google ScholarÂ
Qi, Y.-C. et al. Taurochenodeoxycholic acid mediates cAMP-PKA-CREB signaling pathway. Chin. J. Nat. Med. 18, 898â906 (2020).
Google ScholarÂ
Yang, W. et al. TGR5 agonist inhibits intestinal epithelial cell apoptosis via cAMP/PKA/c-FLIP/JNK signaling pathway and ameliorates dextran sulfate sodium-induced ulcerative colitis. Acta Pharmacol. Sin. 44, 1649â1664 (2023).
Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484â489 (2006).
Google ScholarÂ
Zhao, L.-J. & Zhang, S.-F. Activation of TGR5 promotes mitochondrial biogenesis in human aortic endothelial cells. Biochem. Biophys. Res. Commun. 500, 952â957 (2018).
Google ScholarÂ
Donepudi, A. C., Boehme, S., Li, F. & Chiang, J. Y. L. G protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis. Hepatology 65, 813â827 (2017).
Google ScholarÂ
McGavigan, A. K. et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 66, 226â234 (2017).
Google ScholarÂ
Holter, M. M., Chirikjian, M. K., Govani, V. N. & Cummings, B. P. TGR5 signaling in hepatic metabolic health. Nutrients 12, 2598 (2020).
Google ScholarÂ
Yan, Y. et al. Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism. Nat. Commun. 13, 6408 (2022).
Google ScholarÂ
Lammel Lindemann, J. A. et al. Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7a1) in vitro. Mol. Cell. Endocrinol. 388, 32â40 (2014).
Google ScholarÂ
Bianco, A. C., Sheng, X. Y. & Silva, J. E. Triiodothyronine amplifies norepinephrine stimulation of uncoupling protein gene transcription by a mechanism not requiring protein synthesis. J. Biol. Chem. 263, 18168â18175 (1988).
Google ScholarÂ
de Jesus, L. A. et al. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J. Clin. Invest. 108, 1379â1385 (2001).
Google ScholarÂ
Giudicelli, Y. Thyroid-hormone modulation of the number of beta-adrenergic receptors in rat fat-cell membranes. Biochem. J. 176, 1007â1010 (1978).
Google ScholarÂ
Volke, L. & Krause, K. Effect of thyroid hormones on adipose tissue flexibility. Eur. Thyroid J. 10, 1â9 (2021).
Google ScholarÂ
Lee, J.-Y. et al. Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes. Am. J. Physiol. -Cell Physiol. 302, C463âC472 (2012).
Google ScholarÂ
Periasamy, M. et al. Role of SERCA pump in muscle thermogenesis and metabolism. Compr. Physiol. 7, 879â890 (2017).
Google ScholarÂ
Periasamy, M., Herrera, J. L. & Reis, F. C. G. Skeletal muscle thermogenesis and its role in whole body energy metabolism. Diabetes Metab. J. 41, 327â336 (2017).
Google ScholarÂ
Zekri, Y., Flamant, F. & Gauthier, K. Central vs. peripheral action of thyroid hormone in adaptive thermogenesis: a burning topic. Cells 10, 1327 (2021).
Google ScholarÂ
Brent, G. A. Mechanisms of thyroid hormone action. J. Clin. Invest. 122, 3035â3043 (2012).
Google ScholarÂ
Ventura-Clapier, R., Garnier, A. & Veksler, V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1. Cardiovasc. Res. 79, 208â217 (2008).
Google ScholarÂ
Schmid, A. et al. Evidence of functional bile acid signaling pathways in adipocytes. Mol. Cell. Endocrinol. 483, 1â10 (2019).
Google ScholarÂ
Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829â839 (1998).
Google ScholarÂ
Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115â124 (1999).
Google ScholarÂ
Evans, M. J. & Scarpulla, R. C. NRF-1: a trans-activator of nuclear-encoded respiratory genes in animal cells. Genes Dev. 4, 1023â1034 (1990).
Google ScholarÂ
Virbasius, J. V. & Scarpulla, R. C. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. Proc. Natl Acad. Sci. 91, 1309â1313 (1994).
Google ScholarÂ
Gleyzer, N., Vercauteren, K. & Scarpulla, R. C. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol. Cell. Biol. 25, 1354â1366 (2005).
Google ScholarÂ
Chen, L. et al. PGC-1α-mediated mitochondrial quality control: molecular mechanisms and implications for heart failure. Front. Cell Dev. Biol. 10, 871357 (2022).
Google ScholarÂ
Iwaki, M. et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52, 1655â1663 (2003).
Google ScholarÂ
Berg, A. H. et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947â953 (2001).
Google ScholarÂ
Combs, T. P. et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108, 1875â1881 (2001).
Google ScholarÂ
Hada, Y. et al. Selective purification and characterization of adiponectin multimer species from human plasma. Biochem. Biophys. Res. Commun. 356, 487â493 (2007).
Google ScholarÂ
Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288â1295 (2002).
Google ScholarÂ
Yamauchi, T. et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13, 332â339 (2007).
Google ScholarÂ
Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762â769 (2003).
Google ScholarÂ
Sharma, A. X. & Holland, W. L. Adiponectin and its hydrolase-activated receptors. J. Nat. Sci. 3, e396 (2017).
Google ScholarÂ
Kim, Y. et al. Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice. Cell Death Dis. 13, 1â20 (2022).
Google ScholarÂ
Botta, A. et al. An adiponectin-S1P axis protects against lipid induced insulin resistance and cardiomyocyte cell death via reduction of oxidative stress. Nutr. Metab. 16, 14 (2019).
Google ScholarÂ
Lancaster, G. I. & Febbraio, M. A. Adiponectin sphings into action. Nat. Med. 17, 37â38 (2011).
Google ScholarÂ
Li, Y., Talbot, C. L. & Chaurasia, B. Ceramides in adipose tissue. Front. Endocrinol. 11, 407 (2020).
Google ScholarÂ
Kumar, D. P. et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem. Biophys. Res. Commun. 427, 600â605 (2012).
Google ScholarÂ
Aktories, K. et al. cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacologyâtribute to Karl H. Jakobs. Naunyn. Schmiedebergs Arch. Pharmacol. 392, 887â911 (2019).
Google ScholarÂ
Hamilton, A. et al. Adrenaline stimulates glucagon secretion by Tpc2-dependent Ca2+ mobilization from acidic stores in pancreatic α-cells. Diabetes 67, 1128â1139 (2018).
Google ScholarÂ
Fujimoto, K. et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J. Biol. Chem. 277, 50497â50502 (2002).
Google ScholarÂ
Schmidt, M., Dekker, F. J. & Maarsingh, H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol. Rev. 65, 670â709 (2013).
Google ScholarÂ
Maczewsky, J. et al. TGR5 activation promotes stimulus-secretion coupling of pancreatic β-cells via a PKA-dependent pathway. Diabetes 68, 324â336 (2018).
Google ScholarÂ
Light, P. E., Manning Fox, J. E., Riedel, M. J. & Wheeler, M. B. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol. Endocrinol. 16, 2135â2144 (2002).
Google ScholarÂ
Nakazaki, M. et al. cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 51, 3440â3449 (2002).
Google ScholarÂ
Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409â1439 (2007).
Google ScholarÂ
Vettorazzi, J. F. et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism 65, 54â63 (2016).
Google ScholarÂ
Katsuma, S., Hirasawa, A. & Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386â390 (2005).
Google ScholarÂ
Higuchi, S. et al. Bile acid composition regulates GPR119-dependent intestinal lipid sensing and food intake regulation in mice. Gut 69, 1620â1628 (2020).
Google ScholarÂ
Roberts, R. E. et al. The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. Clin. Endocrinol. 74, 67â72 (2011).
Google ScholarÂ
Kuhre, R. E. et al. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol. Metab. 11, 84â95 (2018).
Google ScholarÂ
Bala, V. et al. Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. Front. Physiol. 5, 420 (2014).
Google ScholarÂ
Gündüz, D. et al. Role of PI3K/Akt and MEK/ERK signalling in cAMP/Epac-mediated endothelial barrier stabilisation. Front. Physiol 10, 1387 (2019).
Google ScholarÂ
Fu, W. & Hall, M. N. Regulation of mTORC2 Signaling. Genes 11, 1045 (2020).
Google ScholarÂ
Cunningham, R. P., Sheldon, R. D. & Rector, R. S. The emerging role of hepatocellular eNOS in non-alcoholic fatty liver disease development. Front. Physiol. 11, 767 (2020).
Google ScholarÂ
Kida, T. et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33, 1663â1669 (2013).
Google ScholarÂ
GarcÃa-Morales, V., Luaces-Regueira, M. & Campos-Toimil, M. The cAMP effectors PKA and Epac activate endothelial NO synthase through PI3K/Akt pathway in human endothelial cells. Biochem. Pharmacol. 145, 94â101 (2017).
Google ScholarÂ
Keitel, V. et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50, 861â870 (2009).
Google ScholarÂ
Flass, T. & Narkewicz, M. R. Cirrhosis and other liver disease in cystic fibrosis. J. Cyst. Fibros. 12, 116â124 (2013).
Google ScholarÂ
Deutschmann, K. et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim. Biophys. Acta BBA – Mol. Basis Dis. 1864, 1319â1325 (2018).
Google ScholarÂ
Beuers, U. et al. The biliary HCO3â umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52, 1489â1496 (2010).
Google ScholarÂ
Hohenester, S. et al. A biliary HCO3â umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55, 173â183 (2012).
Google ScholarÂ
Perino, A. & Schoonjans, K. TGR5 and immunometabolism: insights from physiology and pharmacology. Trends Pharmacol. Sci. 36, 847â857 (2015).
Google ScholarÂ
Descombes, P. & Schibler, U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67, 569â579 (1991).
Google ScholarÂ
Sunilkumar, S., Kimball, S. R. & Dennis, M. D. Glucagon transiently stimulates mTORC1 by activation of an EPAC/Rap1 signaling axis. Cell. Signal. 84, 110010 (2021).
Google ScholarÂ
Chen, H. et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg. Med. Chem. Lett. 22, 4038â4043 (2012).
Google ScholarÂ
Perino, A. et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J. Clin. Invest. 124, 5424â5436 (2014).
Google ScholarÂ
Pols, T. W. H. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14, 747â757 (2011).
Google ScholarÂ
Wang, Y.-D. et al. The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54, 1421â1432 (2011).
Google ScholarÂ
Guo, C. et al. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget 6, 34402â34413 (2015).
Google ScholarÂ
Yoneno, K. et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohnâs disease. Immunology 139, 19â29 (2013).
Google ScholarÂ
Koga, K. et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30, 372â383 (2009).
Google ScholarÂ
Biagioli, M. et al. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J. Immunol. 199, 718â733 (2017).
Google ScholarÂ
Wang, P. et al. p-CREB-1 promotes hepatic fibrosis through the transactivation of transforming growth factor-β1 expression in rats. Int. J. Mol. Med. 38, 521â528 (2016).
Google ScholarÂ
Dempsey, L. A. Bile acids block NLRP3. Nat. Immunol. 17, 1243â1243 (2016).
Google ScholarÂ
Shi, Y. et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation. Front. Immunol. 11, 609060 (2021).
Google ScholarÂ
Liang, H. et al. TGR5 activation attenuates neuroinflammation via Pellino3 inhibition of caspase-8/NLRP3 after middle cerebral artery occlusion in rats. J. Neuroinflammation 18, 40 (2021).
Google ScholarÂ
Högenauer, K. et al. G-Protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. J. Med. Chem. 57, 10343â10354 (2014).
Google ScholarÂ
McMahan, R. H. et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem. 288, 11761â11770 (2013).
Google ScholarÂ
Wammers, M. et al. Reprogramming of pro-inflammatory human macrophages to an anti-inflammatory phenotype by bile acids. Sci. Rep. 8, 255 (2018).
Google ScholarÂ
Liu, R. et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 60, 908â918 (2014).
Google ScholarÂ
Liu, R. et al. Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line. J. Biol. Chem. 290, 30988â31002 (2015).
Google ScholarÂ
Studer, E. et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 55, 267â276 (2012).
Google ScholarÂ
Burg, N., Salmon, J. E. & Hla, T. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat. Rev. Rheumatol. 18, 335â351 (2022).
Google ScholarÂ
Nagahashi, M. et al. Conjugated bile acid activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 61, 1216â1226 (2015).
Google ScholarÂ
Nagahashi, M. et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J. Lipid Res. 57, 1636â1643 (2016).
Google ScholarÂ
Yang, J. et al. Sphingosine 1-phosphate (S1P)/S1P receptor2/3 axis promotes inflammatory M1 polarization of bone marrow-derived monocyte/macrophage via G(α)i/o/PI3K/JNK pathway. Cell. Physiol. Biochem. 49, 1677â1693 (2018).
Google ScholarÂ
Karimian, G. et al. Sphingosine kinase-1 inhibition protects primary rat hepatocytes against bile salt-induced apoptosis. Biochim. Biophys. Acta 1832, 1922â1929 (2013).
Google ScholarÂ
Wang, Y. et al. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology 65, 2005â2018 (2017).
Google ScholarÂ
Wang, X. et al. S1PR2/RhoA/ROCK1 pathway promotes inflammatory bowel disease by inducing intestinal vascular endothelial barrier damage and M1 macrophage polarization. Biochem. Pharmacol. 201, 115077 (2022).
Google ScholarÂ
Schledwitz, A. et al. Differential actions of muscarinic receptor subtypes in gastric, pancreatic, and colon cancer. Int. J. Mol. Sci. 22, 13153 (2021).
Google ScholarÂ
Cheng, K. et al. Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. Biochim. Biophys. Acta 1588, 48â55 (2002).
Google ScholarÂ
Xie, G. et al. Cholinergic agonist-induced pepsinogen secretion from murine gastric chief cells is mediated by M1 and M3 muscarinic receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G521âG529 (2005).
Google ScholarÂ
Zhang, L. et al. High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. OncoTargets Ther. 9, 6719â6726 (2016).
Google ScholarÂ
Von Rosenvinge, E. C. & Raufman, J.-P. Muscarinic receptor signaling in colon cancer. Cancers 3, 971â981 (2011).
Google ScholarÂ
Amonyingcharoen, S. et al. Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. Int. J. Oncol. 46, 2317â2326 (2015).
Google ScholarÂ
Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313â1316 (2002).
Google ScholarÂ
Li, Z. et al. Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells. Physiol. Genom. 45, 268â275 (2013).
Google ScholarÂ
Norman, A. W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542â5548 (2006).
Google ScholarÂ
Nehring, J. A., Zierold, C. & DeLuca, H. F. Lithocholic acid can carry out in vivo functions of vitamin D. Proc. Natl Acad. Sci. USA 104, 10006â10009 (2007).
Google ScholarÂ
Han, S. & Chiang, J. Y. L. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos. Biol. Fate Chem. 37, 469â478 (2009).
Google ScholarÂ
Jurutka, P. W. et al. Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. J. Cell. Biochem. 94, 917â943 (2005).
Google ScholarÂ
Chen, X. et al. Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. Mol. Pharmacol. 69, 1913â1923 (2006).
Google ScholarÂ
McCarthy, T. C., Li, X. & Sinal, C. J. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J. Biol. Chem. 280, 23232â23242 (2005).
Google ScholarÂ
Chatterjee, B., Echchgadda, I. & Song, C. S. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400, 165â191 (2005).
Google ScholarÂ
Honjo, Y. et al. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 188, 635â643 (2006).
Google ScholarÂ
Chow, E. C. Y. et al. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol. Gastroenterology 146, 1048â1059.e7 (2014).
Google ScholarÂ
Ogura, M. et al. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 328, 564â570 (2009).
Google ScholarÂ
Wang, J. et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat. Genet. 48, 1396â1406 (2016).
Google ScholarÂ
Zhang, J., Zhang, Y., Xia, Y. & Sun, J. Imbalance of the intestinal virome and altered viral-bacterial interactions caused by a conditional deletion of the vitamin D receptor. Gut Microbes. 13, 1957408 (2021).
Lamba, V. et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 199, 251â265 (2004).
Google ScholarÂ
Wang, Y.-M., Ong, S. S., Chai, S. C. & Chen, T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8, 803â817 (2012).
Google ScholarÂ
Staudinger, J. L. et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98, 3369â3374 (2001).
Google ScholarÂ
Wistuba, W. et al. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol. 13, 4230â4235 (2007).
Google ScholarÂ
Xie, W. et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98, 3375â3380 (2001).
Google ScholarÂ
Bhalla, S. et al. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279, 45139â45147 (2004).
Google ScholarÂ
Li, T. & Chiang, J. Y. L. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G74âG84 (2005).
Google ScholarÂ
Zhou, J. et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281, 15013â15020 (2006).
Google ScholarÂ
Nakamura, K., Moore, R., Negishi, M. & Sueyoshi, T. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J. Biol. Chem. 282, 9768â9776 (2007).
Google ScholarÂ
Kodama, S., Moore, R., Yamamoto, Y. & Negishi, M. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem. J. 407, 373â381 (2007).
Google ScholarÂ
Choi, H. S. et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272, 23565â23571 (1997).
Google ScholarÂ
Baes, M. et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol. 14, 1544â1552 (1994).
Google ScholarÂ
Kovács, P. et al. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer. Cancers 11, 1255 (2019).
Google ScholarÂ
Wagner, M. et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42, 420â430 (2005).
Google ScholarÂ
Janowski, B. A. et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383, 728â731 (1996).
Google ScholarÂ
Svensson, S. et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 22, 4625â4633 (2003).
Google ScholarÂ
Chuu, C.-P., Kokontis, J. M., Hiipakka, R. A. & Liao, S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14, 543â553 (2007).
Google ScholarÂ
Venkateswaran, A. et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl Acad. Sci. USA 97, 12097â12102 (2000).
Google ScholarÂ
Bideyan, L. et al. Integrative analysis reveals multiple modes of LXR transcriptional regulation in liver. Proc. Natl Acad. Sci. USA 119, e2122683119 (2022).
Google ScholarÂ
Li, S. et al. Adeno-associated virus-based caveolin-1 delivery via different routes for the prevention of cholesterol gallstone formation. Lipids Health Dis. 21, 109 (2022).
Google ScholarÂ
Remaley, A. T. et al. Comparative genome analysis of potential regulatory elements in the ABCG5âABCG8 gene cluster. Biochem. Biophys. Res. Commun. 295, 276â282 (2002).
Google ScholarÂ
Goodwin, B. et al. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 17, 386â394 (2003).
Google ScholarÂ
De Marino, S. et al. Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists. Sci. Rep. 7, 43290 (2017).
Google ScholarÂ
Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720â733 (2015).
Google ScholarÂ
Brocker, C. N. et al. Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. J. Lipid Res. 59, 2140â2152 (2018).
Google ScholarÂ
Zhong, J. et al. Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling. Nat. Commun. 14, 5451 (2023).
Google ScholarÂ
Xie, C. et al. Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864, 1396â1411 (2019).
Google ScholarÂ
Zhang, Y., Lickteig, A. J., Csanaky, I. L. & Klaassen, C. D. Editorâs Highlight: clofibrate decreases bile acids in livers of male mice by increasing biliary bile acid excretion in a PPARα-dependent manner. Toxicol. Sci. 160, 351â360 (2017).
Google ScholarÂ
Brocker, C. N. et al. Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nat. Commun. 11, 5847 (2020).
Google ScholarÂ
Xiong, X. et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J. Hepatol. 60, 847â854 (2014).
Google ScholarÂ
Li, M., Makkinje, A. & Damuni, Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271, 11059â11062 (1996).
Google ScholarÂ
Chaurasia, B. et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 365, 386â392 (2019).
Google ScholarÂ
Bharath, L. P. et al. Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. Diabetes 64, 3914â3926 (2015).
Google ScholarÂ
Stratford, S., Dewald, D. B. & Summers, S. A. Ceramide dissociates 3â²-phosphoinositide production from pleckstrin homology domain translocation. Biochem. J. 354, 359â368 (2001).
Google ScholarÂ
Powell, D. J. et al. Intracellular ceramide synthesis and protein kinase Cζ activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem. J. 382, 619â629 (2004).
Google ScholarÂ
Powell, D. J., Hajduch, E., Kular, G. & Hundal, H. S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCζ-dependent mechanism. Mol. Cell. Biol. 23, 7794â7808 (2003).
Google ScholarÂ
Wu, Q. et al. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J. Clin. Invest. 131, e142865 (2021).
Grebe, A., Hoss, F. & Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 122, 1722â1740 (2018).
Google ScholarÂ
Vandanmagsar, B. et al. The NALP3/NLRP3 inflammasome instigates obesity-induced autoinflammation and insulin resistance. Nat. Med. 17, 179â188 (2011).
Google ScholarÂ
Chen, C.-L. et al. Anti-dengue virus nonstructural protein 1 antibodies cause NO-mediated endothelial cell apoptosis via ceramide-regulated glycogen synthase kinase-3β and NF-κB activation. J. Immunol. 191, 1744â1752 (2013).
Google ScholarÂ
Raichur, S. et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 919 (2014).
Google ScholarÂ
Turpin, S. M. et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678â686 (2014).
Google ScholarÂ
Hammerschmidt, P. et al. CerS6-derived sphingolipids interact with mff and promote mitochondrial fragmentation in obesity. Cell 177, 1536â1552.e23 (2019).
Google ScholarÂ
Prasun, P. Mitochondrial dysfunction in metabolic syndrome. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165838 (2020).
Google ScholarÂ
Chávez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679â1694.e3 (2017).
Google ScholarÂ
Molinaro, A., Wahlström, A. & Marschall, H.-U. Role of bile acids in metabolic control. Trends Endocrinol. Metab. 29, 31â41 (2018).
Google ScholarÂ
Sonne, D. P. et al. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 3002â3009 (2016).
Google ScholarÂ
Cariou, B. et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr. Metab. 8, 48 (2011).
Google ScholarÂ
Li, T. et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J. Biol. Chem. 287, 1861â1873 (2012).
Google ScholarÂ
Haeusler, R. A. et al. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 15, 65â74 (2012).
Google ScholarÂ
Duane, W. C. & Javitt, N. B. 27-Hydroxycholesterol: production rates in normal human subjects. J. Lipid Res. 40, 1194â1199 (1999).
Google ScholarÂ
Haeusler, R. A. et al. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62, 4184â4191 (2013).
Google ScholarÂ
Kaur, A. et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes 64, 1168â1179 (2015).
Google ScholarÂ
Puigserver, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1âPGC-1α interaction. Nature 423, 550â555 (2003).
Google ScholarÂ
Langlet, F. et al. Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell 171, 824â835.e18 (2017).
Google ScholarÂ
Mráz, M. et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol. Res. 60, 627â636 (2011).
Google ScholarÂ
Schreuder, T. C. M. A. et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G440âG445 (2010).
Google ScholarÂ
Kim, H. & Fang, S. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. Lab. Anim. Res. 34, 140â146 (2018).
Google ScholarÂ
Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167â177 (2009).
Google ScholarÂ
Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802â816 (2016).
Google ScholarÂ
Meng, Z. et al. Insufficient bile acid signaling impairs liver repair in CYP27â/â mice. J. Hepatol. 55, 885â895 (2011).
Google ScholarÂ
Zheng, X. et al. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat. Commun. 12, 1487 (2021).
Google ScholarÂ
Zheng, X. et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 33, 791â803.e7 (2021).
Google ScholarÂ
Prinz, P. et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front. Neurosci. 9, 199 (2015).
Google ScholarÂ
Biemann, R. et al. Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial. Sci. Rep. 6, 30173 (2016).
Google ScholarÂ
Li, M. et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice. Nat. Commun. 13, 2060 (2022).
Google ScholarÂ
Li, R. et al. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70â/â mice by reducing fat absorption. J. Lipid Res. 62, 100134 (2021).
Google ScholarÂ
Lee, J.-Y. et al. 12α-Hydroxylated bile acid induces hepatic steatosis with dysbiosis in rats. Biochim. Biophys. Acta BBA – Mol. Cell Biol. Lipids 1865, 158811 (2020).
Google ScholarÂ
Haeusler, R. A. et al. Increased bile acid synthesis and impaired bile acid transport in human obesity. J. Clin. Endocrinol. Metab. 101, 1935â1944 (2016).
Google ScholarÂ
Watanabe, M. et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286, 26913â26920 (2011).
Google ScholarÂ
Prawitt, J. et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 1861â1871 (2011).
Google ScholarÂ
Zhang, Y. et al. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol. Endocrinol. 26, 272â280 (2012).
Google ScholarÂ
Jiao, T. et al. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol. Sin. 43, 1103â1119 (2022).
Google ScholarÂ
Gonzalez, F. J., Jiang, C., Xie, C. & Patterson, A. D. Intestinal farnesoid X receptor signaling modulates metabolic disease. Dig. Dis. 35, 178â184 (2017).
Google ScholarÂ
Lambert, G. et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563â2570 (2003).
Google ScholarÂ
Parséus, A. et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 66, 429â437 (2017).
Google ScholarÂ
Schmitt, J. et al. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver Int. 35, 1133â1144 (2015).
Google ScholarÂ
Velazquez-Villegas, L. A. et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat. Commun. 9, 245 (2018).
Google ScholarÂ
Castellanos-Jankiewicz, A. et al. Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab. 33, 1483â1492.e10 (2021).
Google ScholarÂ
Somm, E. et al. β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight 2, e91809 (2017). 91809.
Google ScholarÂ
Somm, E. et al. β-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice. Am. J. Physiol. Endocrinol. Metab. 315, E833âE847 (2018).
Google ScholarÂ
Wei, M. et al. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. eBioMedicine. 55, 102766 (2020).
Google ScholarÂ
Teodoro, J. S. et al. Chenodeoxycholic acid has non-thermogenic, mitodynamic anti-obesity effects in an in vitro CRISPR/Cas9 model of bile acid receptor TGR5 knockdown. Int. J. Mol. Sci. 22, 11738 (2021).
Google ScholarÂ
Arab, J. P. et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350â362 (2017).
Google ScholarÂ
Bechmann, L. P. et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57, 1394â1406 (2013).
Google ScholarÂ
Jahnel, J. et al. Serum bile acid levels in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 61, 85 (2015).
Google ScholarÂ
Puri, P. et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67, 534â548 (2018).
Google ScholarÂ
Min, H.-K. et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 15, 665â674 (2012).
Google ScholarÂ
Jiao, N. et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 67, 1881â1891 (2018).
Google ScholarÂ
Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731â744 (2000).
Google ScholarÂ
Degirolamo, C. et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology 61, 161â170 (2015).
Google ScholarÂ
Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67, 863â867 (2007).
Google ScholarÂ
Wang, Y. et al. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Front. Pharmacol. 14, 1336216 (2024).
Google ScholarÂ
Yang, Z.-X., Shen, W. & Sun, H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 4, 741â748 (2010).
Google ScholarÂ
Miyata, M. et al. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol. Pharm. Bull. 34, 1885â1889 (2011).
Google ScholarÂ
Kim, I. et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940â946 (2007).
Google ScholarÂ
Kuang, J. et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 35, 1752â1766.e8 (2023).
Google ScholarÂ
Mouzaki, M. et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS ONE 11, e0151829 (2016).
Google ScholarÂ
Zisser, A., Ipsen, D. H. & Tveden-Nyborg, P. Hepatic stellate cell activation and inactivation in NASH-fibrosisâroles as putative treatment targets? Biomedicines 9, 365 (2021).
Google ScholarÂ
Wang, M. et al. Roles of hepatic stellate cells in NAFLD: from the perspective of inflammation and fibrosis. Front. Pharmacol. 13, 958428 (2022).
Google ScholarÂ
Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349â364 (2018).
Google ScholarÂ
Carino, A. et al. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacol. Res. 131, 17â31 (2018).
Google ScholarÂ
Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497â1512 (2004).
Google ScholarÂ
Fiorucci, S. et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor γ contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315, 58â68 (2005).
Google ScholarÂ
Renga, B. et al. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflamm. Res. 60, 577â587 (2011).
Google ScholarÂ
Zhou, J. et al. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat. Commun. 11, 240 (2020).
Google ScholarÂ
Mencarelli, A. et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183, 6657â6666 (2009).
Google ScholarÂ
Zhou, M. et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol. Commun. 1, 1024â1042 (2017).
Google ScholarÂ
Zhou, M. et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914â929 (2016).
Google ScholarÂ
Keitel, V. et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372, 78â84 (2008).
Google ScholarÂ
Xie, G. et al. Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis. eBioMedicine. 66, 103290 (2021).
Google ScholarÂ
Finn, P. D. et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. Am. J. Physiol. Gastrointest. Liver Physiol. 316, G412âG424 (2019).
Google ScholarÂ
Khairnar, R., Islam, M. A., Fleishman, J. & Kumar, S. Shedding light on non-alcoholic fatty liver disease: pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci. 312, 121185 (2023).
Google ScholarÂ
Dowman, J. K., Tomlinson, J. W. & Newsome, P. N. Pathogenesis of non-alcoholic fatty liver disease. QJM Int. J. Med. 103, 71â83 (2010).
Google ScholarÂ
Peng, C. et al. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front. Pharmacol. 11, 603926 (2020).
Google ScholarÂ
Jiao, Y., Lu, Y. & Li, X. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol. Sin. 36, 44â50 (2015).
Google ScholarÂ
Legry, V. et al. Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease? Gut 63, 1â2 (2014).
Google ScholarÂ
Cunningham, J. T. et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450, 736â740 (2007).
Google ScholarÂ
Blättler, S. M. et al. Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab. 15, 505â517 (2012).
Google ScholarÂ
Gordon, S., Akopyan, G., Garban, H. & Bonavida, B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25, 1125â1142 (2006).
Google ScholarÂ
Mu, N. et al. A novel NF-κB/YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes regulates inflammation in rheumatoid arthritis. Sci. Rep. 6, 20059 (2016).
Google ScholarÂ
Stovall, D. B., Sui, G., Stovall, D. B. & Sui, G. In Advances in Prostate Cancer (IntechOpen, 2013).
Van Quickelberghe, E. et al. A protein-protein interaction map of the TNF-induced NF-κB signal transduction pathway. Sci. Data 5, 180289 (2018).
Google ScholarÂ
Ceccarelli, S. et al. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget 6, 41434â41452 (2015).
Google ScholarÂ
Sethi, J. K. & Hotamisligil, G. S. Metabolic Messengers: tumour necrosis factor. Nat. Metab. 3, 1302â1312 (2021).
Google ScholarÂ
Lu, Y. et al. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 63, 170â178 (2014).
Google ScholarÂ
Vasavan, T. et al. Heart and bile acidsâclinical consequences of altered bile acid metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1345â1355 (2018).
Google ScholarÂ
Pu, J. et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur. Heart J. 34, 1834â1845 (2013).
Google ScholarÂ
Rainer, P. P. et al. Bile acids induce arrhythmias in human atrial myocardiumâimplications for altered serum bile acid composition in patients with atrial fibrillation. Heart Br. Card. Soc. 99, 1685â1692 (2013).
Google ScholarÂ
Nilsson, L.-M. et al. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem. Biophys. Res. Commun. 357, 707â711 (2007).
Google ScholarÂ
Hanniman, E. A., Lambert, G., McCarthy, T. C. & Sinal, C. J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595â2604 (2005).
Google ScholarÂ
Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101, 3668â3673 (2004).
Google ScholarÂ
Li, Y. T. Y. et al. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27, 2606â2611 (2007).
Google ScholarÂ
Zhang, Y. et al. FXR deficiency causes reduced atherosclerosis in Ldlrâ/â mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316â2321 (2006).
Google ScholarÂ
Guo, G. L. et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761, 1401â1409 (2006).
Google ScholarÂ
Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956â965 (2015).
Google ScholarÂ
Desai, M. S. et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51, 2097â2107 (2010).
Google ScholarÂ
Fryer, R. M. et al. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism. J. Pharmacol. Exp. Ther. 348, 421â431 (2014).
Google ScholarÂ
Eblimit, Z. et al. TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. Cardiovasc. Ther. 36, e12462 (2018).
Google ScholarÂ
Duboc, H. et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor? Hepatology 56, 2426 (2012).
Google ScholarÂ
Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121â141 (2014).
Google ScholarÂ
Inagaki, T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. USA 103, 3920â3925 (2006).
Google ScholarÂ
Begley, M., Gahan, C. G. M. & Hill, C. The interaction between bacteria and bile. FEMS Microbiol. Rev. 29, 625â651 (2005).
Google ScholarÂ
Ãbeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 64, 1049â1057 (2016).
Google ScholarÂ
Bernstein, H., Bernstein, C., Payne, C. M. & Dvorak, K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J. Gastroenterol. 15, 3329â3340 (2009).
Google ScholarÂ
Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205â208 (2015).
Google ScholarÂ
Massafra, V. et al. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim. Biophys. Acta 1862, 166â173 (2016).
Google ScholarÂ
Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463â472 (2011).
Google ScholarÂ
Ceulemans, L. J. et al. Farnesoid X receptor activation attenuates intestinal ischemia reperfusion injury in rats. PLoS ONE 12, e0169331 (2017).
Google ScholarÂ
Verbeke, L. et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am. J. Pathol. 185, 409â419 (2015).
Google ScholarÂ
Nijmeijer, R. M. et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory Bowel disease. PLoS ONE 6, e23745 (2011).
Google ScholarÂ
Cipriani, S. et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6, e25637 (2011).
Google ScholarÂ
Ichikawa, R. et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 136, 153â162 (2012).
Google ScholarÂ
Devlin, A. S. & Fischbach, M. A. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat. Chem. Biol. 11, 685â690 (2015).
Google ScholarÂ
Josefowicz, S. Z. et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482, 395â399 (2012).
Google ScholarÂ
Chang, D. et al. The conserved non-coding sequences CNS6 and CNS9 control cytokine-induced rorc transcription during T helper 17 cell differentiation. Immunity 53, 614â626.e4 (2020).
Google ScholarÂ
Yang, B.-H. et al. Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol. 9, 444â457 (2016).
Google ScholarÂ
Song, X. et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature 577, 410â415 (2020).
Google ScholarÂ
Hang, S. et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576, 143â148 (2019).
Google ScholarÂ
Paik, D. et al. Human gut bacteria produce ΤÎ17-modulating bile acid metabolites. Nature 603, 907â912 (2022).
Google ScholarÂ
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655â662 (2019).
Google ScholarÂ
Sinha, S. R. et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27, 659â670.e5 (2020).
Google ScholarÂ
Das, P., Marcišauskas, S., Ji, B. & Nielsen, J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics 20, 517 (2019).
Google ScholarÂ
Hsu, C. L. & Schnabl, B. The gutâliver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol. 21, 719â733 (2023).
Google ScholarÂ
Yan, M. et al. Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduct. Target. Ther. 8, 1â26 (2023).
Fukunishi, S. et al. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J. Clin. Biochem. Nutr. 54, 39â44 (2014).
Google ScholarÂ
Alonso-Peña, M. et al. Impact of liver inflammation on bile acid side chain shortening and amidation. Cells 11, 3983 (2022).
Google ScholarÂ
Venkatesh, M. et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity 41, 296â310 (2014).
Google ScholarÂ
Little, M. et al. Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice. Acta Pharm. Sin. B. 12, 801â820 (2022).
Google ScholarÂ
Phelan, J. P. et al. Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget 8, 115736â115747 (2017).
Google ScholarÂ
Yasuda, H. et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem. Biophys. Res. Commun. 354, 154â159 (2007).
Google ScholarÂ
Nagathihalli, N. S. et al. Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 74, 2062â2072 (2014).
Google ScholarÂ
Wu, J., Gong, J., Geng, J. & Song, Y. Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. BMC Cancer 8, 333 (2008).
Google ScholarÂ
Ward, J. B. J. et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G550âG558 (2017).
Google ScholarÂ
Ni, Z. et al. TGR5-HNF4α axis contributes to bile acid-induced gastric intestinal metaplasia markers expression. Cell Death Discov. 6, 56 (2020).
Google ScholarÂ
Xu, Z. et al. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell. Signal. 24, 1658â1664 (2012).
Google ScholarÂ
Anwer, M. S. Intracellular signaling by bile acids. J. Bio Sci. 20, 1â23 (2012).
Google ScholarÂ
Bernstein, H. et al. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589, 47â65 (2005).
Google ScholarÂ
Jia, W., Xie, G. & Jia, W. Bile acidâmicrobiota cross-talk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111â128 (2018).
Google ScholarÂ
Yao, Z. et al. Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor bortezomib. ACS Chem. Neurosci. 11, 1337â1346 (2020).
Google ScholarÂ
Lee, S. et al. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. Int. J. Mol. Med. 42, 2551â2559 (2018).
Google ScholarÂ
Liu, H. et al. Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J. Gastroenterol. 13, 1652â1658 (2007).
Google ScholarÂ
Lim, S.-C., Choi, J. E., Kang, H. S. & Han, S. I. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int. J. Cancer 126, 1582â1595 (2010).
Google ScholarÂ
Wu, Y.-C., Chiu, C.-F., Hsueh, C.-T. & Hsueh, C.-T. The role of bile acids in cellular invasiveness of gastric cancer. Cancer Cell Int. 18, 75 (2018).
Google ScholarÂ
Lim, S.-C. et al. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis 32, 723â731 (2011).
Google ScholarÂ
Im, E. & Martinez, J. D. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J. Nutr. 134, 483â486 (2004).
Google ScholarÂ
Im, E., Akare, S., Powell, A. & Martinez, J. D. Ursodeoxycholic acid can suppress deoxycholic acid-induced apoptosis by stimulating Akt/PKB-dependent survival signaling. Nutr. Cancer 51, 110â116 (2005).
Google ScholarÂ
Saeki, T. et al. Ursodeoxycholic acid protects colon cancer HCT116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation. Nutr. Cancer 64, 617â626 (2012).
Google ScholarÂ
Alpini, G. et al. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G973âG982 (2004).
Google ScholarÂ
Mikó, E. et al. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochim. Biophys. Acta Bioenerg. 1859, 958â974 (2018).
Google ScholarÂ
Goldberg, A. A., Titorenko, V. I., Beach, A. & Sanderson, J. T. Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells. PeerJ 1, e122 (2013).
Google ScholarÂ
Jin, Q. et al. Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells. Eur. J. Cancer Prev. 27, 553â556 (2018).
Google ScholarÂ
Song, W. et al. Apoptosis of human gastric carcinoma SGC-7901 induced by deoxycholic acid via the mitochondrial-dependent pathway. Appl. Biochem. Biotechnol. 171, 1061â1071 (2013).
Google ScholarÂ
Sun, J. et al. Lithocholic acid down-regulation of NF-kappaB activity through vitamin D receptor in colonic cancer cells. J. Steroid Biochem. Mol. Biol. 111, 37â40 (2008).
Google ScholarÂ
Vogel, S. M. et al. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc. Natl Acad. Sci. USA 109, 16906â16910 (2012).
Google ScholarÂ
Luu, T. H. et al. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell. Oncol. Dordr. 41, 13â24 (2018).
Google ScholarÂ
Fukase, K. et al. Bile acids repress E-cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma. Cancer Sci. 99, 1785â1792 (2008).
Google ScholarÂ
Yoon, J.-H. et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122, 985â993 (2002).
Google ScholarÂ
Debruyne, P. R. et al. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 21, 6740â6750 (2002).
Google ScholarÂ
Yu, J.-H. et al. Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int. J. Oncol. 54, 879â892 (2019).
Google ScholarÂ
Carino, A. et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget 7, 61021â61035 (2016).
Google ScholarÂ
Jang, E. S. et al. Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. J. Cancer Res. Clin. Oncol. 140, 133â144 (2014).
Google ScholarÂ
Yen, C.-J. et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrettâs-associated esophageal adenocarcinoma. Cancer Res. 68, 2632â2640 (2008).
Google ScholarÂ
Prichard, D. O. et al. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrettâs oesophagus by modulating integrin-αv trafficking. J. Cell. Mol. Med. 21, 3612â3625 (2017).
Google ScholarÂ
Joshi, S. et al. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Mol. Oncol. 10, 1063â1077 (2016).
Google ScholarÂ
Liu, X. et al. The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer. Cancer Lett. 412, 194â207 (2018).
Google ScholarÂ
Krishnamurthy, K., Wang, G., Rokhfeld, D. & Bieberich, E. Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Res. BCR 10, R106 (2008).
Google ScholarÂ
Chen, Z. et al. The role of fibroblast growth factor 19 in hepatocellular carcinoma. Am. J. Pathol. 191, 1180â1192 (2021).
Google ScholarÂ
Liu, Y. et al. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front. Cell Dev. Biol. 8, 95 (2020).
Google ScholarÂ
Zou, Y. et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat. Commun. 13, 2672 (2022).
Google ScholarÂ
Liu, J. et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target. Ther. 7, 1â23 (2022).
Wang, Y. et al. Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases. Signal Transduct. Target. Ther. 8, 1â45 (2023).
Lewerenz, J. et al. The cystine/glutamate antiporter system xcâ in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18, 522â555 (2013).
Google ScholarÂ
Iseda, N. et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptorâ4 inhibition in hepatocellular carcinoma. Cancer Sci. 113, 2272â2287 (2022).
Google ScholarÂ
Qi, Y. et al. The bile acid membrane receptor TGR5 in cancer: friend or foe? Molecules 27, 5292 (2022).
Google ScholarÂ
Xiong, Q. et al. Metabolite-sensing G protein coupled receptor TGR5 protects host from viral infection through amplifying type I interferon responses. Front. Immunol. 9, 2289 (2018).
Google ScholarÂ
Hu, M.-M. et al. Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. Cell Res. 29, 193â205 (2019).
Google ScholarÂ
Gulen, M. F. et al. cGASâSTING drives ageing-related inflammation and neurodegeneration. Nature 620, 374â380 (2023).
Google ScholarÂ
Ou, L., Zhang, A., Cheng, Y. & Chen, Y. The cGAS-STING pathway: a promising immunotherapy target. Front. Immunol. 12, 795048 (2021).
Google ScholarÂ
Zhang, Y. et al. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. Pharmacol. Res. Perspect. 5, e00329 (2017).
Google ScholarÂ
Zhang, Y. et al. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models. Pharmacol. Res. Perspect. 5, e00368 (2017).
Google ScholarÂ
Ratziu, Y. et al. EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study. J. Hepatol. 76, 506â517 (2022).
Google ScholarÂ
Pellicciari, R. et al. Discovery of 3α,7α,11β-trihydroxy-6α-ethyl-5β-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders. J. Med. Chem. 59, 9201â9214 (2016).
Google ScholarÂ
Soisson, S. M. et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl Acad. Sci. USA 105, 5337â5342 (2008).
Google ScholarÂ
Zhang, C. et al. Discovery of betulinic acid derivatives as potent intestinal farnesoid X receptor antagonists to ameliorate nonalcoholic steatohepatitis. J. Med. Chem. 65, 13452â13472 (2022).
Google ScholarÂ
Panzitt, K., Zollner, G., Marschall, H.-U. & Wagner, M. Recent advances on FXR-targeting therapeutics. Mol. Cell. Endocrinol. 552, 111678 (2022).
Google ScholarÂ
Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513â1530 (2013).
Google ScholarÂ
Gege, C. et al. Knocking on FXRâs Door: The. Curr. Top. Med. Chem. 14, 2143â2158 (2014).
Dwivedi, S. K. D. et al. Bile acid receptor agonist GW4064 regulates PPARγ COactivator-1α Expression through Estrogen Receptor-related Receptor α. Mol. Endocrinol. 25, 922â932 (2011).
Google ScholarÂ
Gege, C. et al. In Bile Acids and Their Receptors (eds. Fiorucci, S. & Distrutti, E.) 167â205 (Springer International Publishing, 2019).
Tully, D. C. et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J. Med. Chem. 60, 9960â9973 (2017).
Google ScholarÂ
Patel, K. et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72, 58â71 (2020).
Google ScholarÂ
Jiang, L. et al. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor. Biochem. Biophys. Res. Commun. 595, 1â6 (2022).
Google ScholarÂ
Kremoser, C. FXR agonists for NASH: how are they different and what difference do they make? J. Hepatol. 75, 12â15 (2021).
Google ScholarÂ
Trauner, M. et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GSâ9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 70, 788 (2019).
Google ScholarÂ
Al-Khaifi, A., Rudling, M. & Angelin, B. An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers. Gastroenterology 155, 1012â1016 (2018).
Google ScholarÂ
Traussnigg, S. et al. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wien. Klin. Wochenschr. 133, 441â451 (2021).
Google ScholarÂ
Chianelli, D. et al. Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. J. Med. Chem. 63, 3868â3880 (2020).
Google ScholarÂ
Wang, Y. et al. Safety, pharmacokinetics, pharmacodynamics, and formulation of liverâdistributed farnesoid Xâreceptor agonist TERNâ101 in healthy volunteers. Clin Pharmacol Drug Dev 10, 1198â1208 (2021).
Google ScholarÂ
Genin, M. J. et al. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid: a novel FXR agonist for the treatment of dyslipidemia. J. Med. Chem. 58, 9768â9772 (2015).
Google ScholarÂ
Carpenter, J. et al. Discovery of BMS-986318, a potent nonbile acid FXR agonist for the treatment of nonalcoholic steatohepatitis. ACS Med. Chem. Lett. 12, 1413â1420 (2021).
Google ScholarÂ
Nara, S. J. et al. Discovery of BMS-986339, a pharmacologically differentiated farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis. J. Med. Chem. 65, 8948â8960 (2022).
Google ScholarÂ
Mo, C. et al. Discovery of HPG1860, a structurally novel nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitis. J. Med. Chem. 66, 9363â9375 (2023).
Google ScholarÂ
Flatt, B. et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52, 904â907 (2009).
Google ScholarÂ
Evans, M. J. et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G543âG552 (2009).
Google ScholarÂ
Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell. 11, 1079â1092 (2003).
Google ScholarÂ
Fang, S. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159â165 (2015).
Google ScholarÂ
Harrison, S. A. et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J. Hepatol. 75, 25â33 (2021).
Google ScholarÂ
Wang, H. et al. A novel intestinal-restricted FXR agonist. Bioorg. Med. Chem. Lett. 27, 3386â3390 (2017).
Google ScholarÂ
Huang, W. et al. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease. Bioorg. Chem. 143, 107071 (2024).
Google ScholarÂ
Chen, C. et al. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis. Eur. J. Med. Chem. 264, 115992 (2024).
Google ScholarÂ
Xi, L. et al. Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies. Front. Pharmacol. 14, 1197856 (2023).
Google ScholarÂ
Yao, Z. et al. The discovery of a new potent FXR agonist based on natural product screening. Bioorg. Chem. 143, 106979 (2024).
Google ScholarÂ
Liu, Y. et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112, 1678â1687 (2003).
Google ScholarÂ
Jin, D. et al. Farnesoid X receptor activation protects liver from ischemia/reperfusion injury by up-regulating small heterodimer partner in Kupffer cells. Hepatol. Commun. 4, 540â554 (2020).
Google ScholarÂ
Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51, 380â388 (2009).
Google ScholarÂ
Liu, X. et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem. Biophys. Res. Commun. 450, 117â123 (2014).
Google ScholarÂ
Hartman, H. B. et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLRâ/â and apoEâ/â mice. J. Lipid Res. 50, 1090â1100 (2009).
Google ScholarÂ
Hernandez, E. D. et al. Tropifexorâmediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol. Commun. 3, 1085â1097 (2019).
Google ScholarÂ
Schwabl, P. et al. The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model. Biomedicines 9, 60 (2021).
Google ScholarÂ
Papazyan, R. et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J. Lipid Res. 59, 982â993 (2018).
Google ScholarÂ
Miyata, S. et al. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Sci. Rep. 11, 9196 (2021).
Google ScholarÂ
Nemetchek, M. D. et al. A structural mechanism of nuclear receptor biased agonism. Proc. Natl Acad. Sci. USA 119, e2215333119 (2022).
Google ScholarÂ
Pathak, P. et al. Intestine farnesoid X receptor agonist and the gut microbiota activate Gâprotein bile acid receptorâ1 signaling to improve metabolism. Hepatology 68, 1574 (2018).
Google ScholarÂ
Zhou, W., Akinrotimi, O., Dadlani, N. & Anakk, S. FXR regulates adipose tissue remodeling during obesity. FASEB J. 35, S1 (2021).
Li, H. et al. Ursodeoxycholic acid treatment restores gut microbiota and alleviates liver inflammation in non-alcoholic steatohepatitic mouse model. Front. Pharmacol. 12, 788558 (2021).
Google ScholarÂ
Ahmad, Z. et al. Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur. J. Endocrinol. 168, 771â778 (2013).
Google ScholarÂ
Rao, A. S. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139, 1549â1558 (2010).
Google ScholarÂ
Enanta Pharmaceuticals, Inc. A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA) (2021).
US National Library of Medicine. ClinicalTrials.gov (NCT01998659) (2014).
US National Library of Medicine. ClinicalTrials.gov (NCT00499629) https://clinicaltrials.gov/study/NCT00499629 (2008).
US National Library of Medicine. ClinicalTrials.gov (NCT00509756) https://clinicaltrials.gov/study/NCT00509756 (2010) .
US National Library of Medicine. ClinicalTrials.gov (NCT03890120) (2023).
Sanyal, A. J. et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Nat. Med. 29, 392â400 (2023).
Google ScholarÂ
Schramm, C. et al. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. JHEP Rep. Innov. Hepatol. 4, 100544 (2022).
Google ScholarÂ
Hepagene (Shanghai) Co., Ltd. A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPG1860 (2022).
Hepagene (Shanghai) Co., Ltd. A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis (2022).
Terns, Inc. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) (2022).
Terns, Inc. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as Well as in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NASH) (2023).
Metacrine, Inc. A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH) (2021).
Calderon, G. et al. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine 55, 102759 (2020).
Google ScholarÂ
Sinha, S. R. The Role of Secondary Bile Acids in Intestinal Inflammation (2023).
First Affiliated Hospital Xiâan Jiaotong University. Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin-A Multicenter, Prospective, Random Controlled Trial (2022).
Mueller, M. et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 62, 1398â1404 (2015).
Google ScholarÂ
Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631â643 (2016).
Google ScholarÂ
Kowdley, K. V. et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J. Hepatol. 73, 94â101 (2020).
Google ScholarÂ
Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574â582.e1 (2013).
Google ScholarÂ
US National Library of Medicine. ClinicalTrials.gov (NCT00501592) (2012).
Siddiqui, M. S. et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J. Hepatol. 72, 25â33 (2020).
Google ScholarÂ
Pockros, P. J. et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 39, 2082â2093 (2019).
Google ScholarÂ
Sanyal, A. J. et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J. Hepatol. 79, 1110â1120 (2023).
Google ScholarÂ
Xu, J. et al. ILâ31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology 77, 20 (2023).
Google ScholarÂ
Intercept Pharmaceuticals, Inc. 2023 Q2 – Results – Earnings Call Presentation (NASDAQ:ICPT) | Seeking Alpha (2023).
Di Pasqua, L. G. et al. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH. Liver Int. 44, 214â227 (2024).
Google ScholarÂ
Intercept Pharmaceuticals. Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis. https://www.interceptpharma.com/about-us/news/?id=2550372(2022).
Intercept Pharmaceuticals. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis (2024).
Burris, T. P. et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacol. Rev. 65, 710â778 (2013).
Google ScholarÂ
Thomas, A. M. et al. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51, 1410â1419 (2010).
Google ScholarÂ
Massafra, V., Pellicciari, R., Gioiello, A. & van Mil, S. W. C. Progress and challenges of selective farnesoid X receptor modulation. Pharmacol. Ther. 191, 162â177 (2018).
Google ScholarÂ
Pellicciari, R. et al. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J. Med. Chem. 49, 4208â4215 (2006).
Google ScholarÂ
Meijer, F. A., Leijten-van de Gevel, I. A., de Vries, R. M. J. M. & Brunsveld, L. Allosteric small molecule modulators of nuclear receptors. Mol. Cell. Endocrinol. 485, 20â34 (2019).
Google ScholarÂ
Kim, D. et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 34, 184â199 (2015).
Google ScholarÂ
Renga, B. et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE 7, e30443 (2012).
Google ScholarÂ
Urizar, N. L. et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296, 1703â1706 (2002).
Google ScholarÂ
Wu, J. et al. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol. Endocrinol. 16, 1590â1597 (2002).
Google ScholarÂ
Cui, J. et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278, 10214â10220 (2003).
Google ScholarÂ
Szapary, P. O. et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290, 765â772 (2003).
Google ScholarÂ
Pellicciari, R. et al. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958â7961 (2009).
Google ScholarÂ
Renga, B. et al. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT/FOXOA1 dependent regulation of H2S generation and endothelin-1. PLoS ONE 10, e0141082 (2015).
Google ScholarÂ
Yang, F. et al. Structural basis of GPBAR activation and bile acid recognition. Nature 587, 499â504 (2020).
Google ScholarÂ
Li, Y. et al. Discovery and biological evaluation of cholic acid derivatives as potent TGR5 positive allosteric modulators. Bioorg. Med. Chem. 92, 117418 (2023).
Google ScholarÂ
Nakhi, A. et al. 7-Methylation of chenodeoxycholic acid derivatives yields a substantial increase in TGR5 receptor potency. J. Med. Chem. 62, 6824â6830 (2019).
Google ScholarÂ
Sato, H. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 362, 793â798 (2007).
Google ScholarÂ
Genet, C. et al. Structureâactivity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J. Med. Chem. 53, 178â190 (2010).
Google ScholarÂ
Budzik, B. W. et al. Synthesis and structureâactivity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists. Bioorg. Med. Chem. Lett. 20, 1363â1367 (2010).
Google ScholarÂ
Evans, K. A. et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J. Med. Chem. 52, 7962â7965 (2009).
Google ScholarÂ
Hodge, R. J. et al. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in betes. Clin. Pharmacol. Drug Dev. 2, 213â222 (2013).
Google ScholarÂ
Herbert, M. R. et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg. Med. Chem. Lett. 20, 5718â5721 (2010).
Google ScholarÂ
Futatsugi, K. et al. Optimization of triazole-based TGR5 agonists towards orally available agents. MedChemComm 4, 205â210 (2012).
Google ScholarÂ
Piotrowski, D. W. et al. Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists. ACS Med. Chem. Lett. 4, 63â68 (2012).
Google ScholarÂ
Agarwal, S. et al. Discovery of a potent and orally efficacious TGR5 receptor agonist. ACS Med. Chem. Lett. 7, 51â55 (2015).
Google ScholarÂ
Phillips, D. P. et al. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structureâactivity relationships, lead optimization, and chronic in vivo efficacy. J. Med. Chem. 57, 3263â3282 (2014).
Google ScholarÂ
Zambad, S. P. et al. TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab. Syndr. Obes. Targets Ther. 7, 1â14 (2013).
Zhao, S. et al. Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists. RSC Adv. 12, 3618â3629 (2022).
Picon, S. et al. Discovery, structureâactivity relationships, and in vivo activity of dihydropyridone agonists of the bile acid receptor TGR5. J. Med. Chem. 66, 11732â11760 (2023).
Google ScholarÂ
Duan, H. et al. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J. Med. Chem. 55, 10475â10489 (2012).
Google ScholarÂ
Briere, D. A. et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS ONE 10, e0136873 (2015).
Google ScholarÂ
de Oliveira, M. C. et al. Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice. Biochim. Biophys. Acta BBA Mol. Basis Dis. 1862, 2054â2062 (2016).
Google ScholarÂ
Carino, A. et al. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci. Rep. 7, 13689 (2017).
Google ScholarÂ
Miyazaki-Anzai, S. et al. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J. Lipid Res. 59, 1709â1713 (2018).
Google ScholarÂ
Miyazaki-Anzai, S. et al. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS ONE 9, e108270 (2014).
Google ScholarÂ
Li, T. et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 25, 1066â1071 (2011).
Google ScholarÂ
Zhuo, N. et al. Discovery of betulinic acid derivatives as gut-restricted TGR5 agonists: Balancing the potency and physicochemical properties. Bioorg. Chem. 144, 107132 (2024).
Google ScholarÂ
Brighton, C. A. et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G proteinâcoupled bile acid receptors. Endocrinology 156, 3961â3970 (2015).
Google ScholarÂ
Tough, I. R., Schwartz, T. W. & Cox, H. M. Synthetic G protein-coupled bile acid receptor agonists and bile acids act via basolateral receptors in ileal and colonic mucosa. Neurogastroenterol. Motil. 32, e13943 (2020).
Google ScholarÂ
Lasalle, M. et al. Topical intestinal aminoimidazole agonists of G-protein-coupled bile acid receptor 1 promote glucagon like peptide-1 secretion and improve glucose tolerance. J. Med. Chem. 60, 4185â4211 (2017).
Google ScholarÂ
Duan, H. et al. Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes. J. Med. Chem. 58, 3315â3328 (2015).
Google ScholarÂ
Cao, H. et al. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect. Sci. Rep. 6, 28676 (2016).
Google ScholarÂ
Chen, T. et al. Design of gut-restricted thiazolidine agonists of G protein-coupled bile acid receptor 1 (GPBAR1, TGR5). J. Med. Chem. 61, 7589â7613 (2018).
Google ScholarÂ
Hoguet, V. et al. Beyond the rule of 5: impact of PEGylation with various polymer sizes on pharmacokinetic properties, structureâproperties relationships of mPEGylated small agonists of TGR5 receptor. J. Med. Chem. 64, 1593â1610 (2021).
Google ScholarÂ
Zou, Q. et al. 4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists. Eur. J. Med. Chem. 82, 1â15 (2014).
Google ScholarÂ
Han, F. et al. Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects. Eur. J. Med. Chem. 203, 112619 (2020).
Google ScholarÂ
Kim, H. S. & Jung, C. H. Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: could it be a magic bullet for type 2 diabetes? Int. J. Mol. Sci. 22, 9936 (2021).
Google ScholarÂ
Comeglio, P. et al. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. J. Endocrinol. 238, 107â127 (2018).
Google ScholarÂ
Jadhav, K. et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol. Metab. 9, 131â140 (2018).
Google ScholarÂ
Hu, Y.-B., Liu, X.-Y. & Zhan, W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des. Devel. Ther. 12, 2213â2221 (2018).
Google ScholarÂ
Gu, M. et al. Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor/G protein-coupled bile acid receptor 1 activation and leptin sensitization. Phytother. Res. 37, 2771â2786 (2023).
Google ScholarÂ
Sarvagalla, S., Kolapalli, S. P. & Vallabhapurapu, S. The two sides of YY1 in cancer: a friend and a foe. Front. Oncol. 9, 1230 (2019).
Vega, M. I., Jazirehi, A. R., Huerta-Yepez, S. & Bonavida, B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in ramos non-Hodgkinâs lymphoma cell line via inhibition of NF-κB activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J. Immunol. 175, 2174â2183 (2005).
Google ScholarÂ
Garbán, H. J. & Bonavida, B. Nitric oxide inhibits the transcription repressor yin-yang 1 binding activity at the silencer region of the fas promoter: a pivotal role for nitric oxide in the up-regulation of fas gene expression in human tumor cells. J. Immunol. 167, 75â81 (2001).
Google ScholarÂ
Bonavida, B. & Baritaki, S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. Nitric Oxide 24, 1â7 (2011).
Google ScholarÂ
Zhang, N. et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 32, 5078â5088 (2013).
Google ScholarÂ
Huang, T. et al. MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. Cancer Biomark. 21, 221â228 (2018).
Google ScholarÂ
Zhang, Y. et al. miRâ29a suppresses ILâ13âinduced cell invasion by inhibiting YY1 in the AKT pathway in lung adenocarcinoma A549 cells. Oncol. Rep. 39, 2613â2623 (2018).
Google ScholarÂ
Zhou, W.-Y. et al. MicroRNA-181 targets Yin Yang 1 expression and inhibits cervical cancer progression. Mol. Med. Rep. 11, 4541â4546 (2015).
Google ScholarÂ
Gao, Y. et al. miRâ218 inhibits the proliferation of human glioma cells through downregulation of Yin Yang 1. Mol. Med. Rep. 17, 1926â1932 (2018).
Google ScholarÂ
Huang, W. et al. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone. Bioorg. Med. Chem. 75, 117073 (2022).
Google ScholarÂ
Ren, Q. et al. Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease. J. Med. Chem. 66, 6082â6104 (2023).
Google ScholarÂ
Fiorucci, S. et al. Discovery of a potent and orally active dual GPBAR1/CysLT1R modulator for the treatment of metabolic fatty liver disease. Front. Pharmacol. 13, 858137 (2022).
Google ScholarÂ
Fiorillo, B. et al. Discovery of a novel class of dual GPBAR1 agonistsâRORγt inverse agonists for the treatment of IL-17-mediated disorders. ACS Omega 8, 5983â5994 (2023).
Google ScholarÂ
Shiragannavar, V. D. et al. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator. Front. Pharmacol. 14, 1135952 (2023).
Google ScholarÂ
Festa, C. et al. Investigation around the oxadiazole core in the discovery of a new chemotype of potent and selective FXR antagonists. ACS Med. Chem. Lett. 10, 504â510 (2019).
Google ScholarÂ
Finamore, C. et al. Expanding the library of 1,2,4-oxadiazole derivatives: discovery of new farnesoid X receptor (FXR) antagonists/pregnane X receptor (PXR) agonists. Molecules 28, 2840 (2023).
Google ScholarÂ
Yamashita, Y. et al. Discovery of FXR/PPARγ dual partial agonist. Bioorg. Med. Chem. 85, 117238 (2023).
Google ScholarÂ
Lebovitz, H. E. Thiazolidinediones: the forgotten diabetes medications. Curr. Diab. Rep. 19, 151 (2019).
Google ScholarÂ
Liu, J., Carlson, H. A. & Scott, E. E. The structure and characterization of human cytochrome P450 8B1 supports future drug design for nonalcoholic fatty liver disease and diabetes. J. Biol. Chem. 298, 102344 (2022).
DePaoli, A. M. et al. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis. Diabetes 68, 1315â1328 (2019).
Google ScholarÂ
Harrison, S. A. et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 71, 1198â1212 (2020).
Google ScholarÂ
Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 391, 1174â1185 (2018).
Google ScholarÂ
Liu, Y. et al. Novel regulatory factors and small-molecule inhibitors of FGFR4 in cancer. Front. Pharmacol. 12, 633453 (2021).
Lang, L. & Teng, Y. Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells 8, 31 (2019).
Google ScholarÂ
Chen, X. et al. Insight into the design of FGFR4 selective inhibitors in cancer therapy: prospects and challenges. Eur. J. Med. Chem. 263, 115947 (2024).
Google ScholarÂ
Zhao, H.-Y. et al. Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands. J. Med. Chem. 65, 4709â4726 (2022).
Google ScholarÂ
Ma, L. et al. Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer. J. Med. Chem. 66, 7438â7453 (2023).
Google ScholarÂ
Harach, T. et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2, 430 (2012).
Google ScholarÂ
Shang, Q. et al. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G419âG424 (2010).
Google ScholarÂ
Nwose, O. M. & Jones, M. R. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin. Med. Insights Endocrinol. Diabetes 6, 75â79 (2013).
Google ScholarÂ
Brufau, G. et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52, 1455â1464 (2010).
Google ScholarÂ
Hansen, M. et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J. Diabetes Complications. 31, 918â927 (2017).
Google ScholarÂ
Potthoff, M. J. et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G371âG380 (2013).
Google ScholarÂ
West, K. L. et al. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis 171, 201â210 (2003).
Google ScholarÂ
Miethke, A. G. et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 63, 512â523 (2016).
Google ScholarÂ
West, K. L. et al. 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J. Pharmacol. Exp. Ther. 303, 293â299 (2002).
Google ScholarÂ
Al-Dury, S. et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci. Rep. 8, 6658 (2018).
Google ScholarÂ
Baghdasaryan, A. et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J. Hepatol. 64, 674â681 (2016).
Google ScholarÂ
Mirum Pharmaceuticals, Inc. MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFIC (2023).
Mirum Pharmaceuticals, Inc. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis (2024).
Mirum Pharmaceuticals, Inc. A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis (2024).
Li, L. et al. Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease. Front. Immunol. 13, 974305 (2022).
Google ScholarÂ
Devlin, S. Bacterial modification of bile acids alters host physiology. FASEB J. 33, 93.2â93.2 (2019).
Google ScholarÂ
de Bruijn, V. et al. Antibiotic-induced changes in microbiome-related metabolites and bile acids in rat plasma. Metabolites 10, 242 (2020).
Google ScholarÂ
Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919â1929 (2018).
Google ScholarÂ
Degirolamo, C. et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 7, 12â18 (2014).
Google ScholarÂ
Mencarelli, A. et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 7, e45425 (2012).
Google ScholarÂ
Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 29, 2919â2928 (2023).
Google ScholarÂ
Sari, G. et al. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem. Biophys. Res. Commun. 524, 510â515 (2020).
Google ScholarÂ
Guo, G. L. & Chiang, J. Y. L. Is CYP2C70 the key to new mouse models to understand bile acids in humans? J. Lipid Res. 61, 269â271 (2020).
Google ScholarÂ
Hasan, M. N. et al. Glycine-β-muricholic acid improves liver fibrosis and gut barrier function by reducing bile acid pool size and hydrophobicity in male Cyp2c70 knockout mice. Cells 12, 1371 (2023).
Google ScholarÂ
Takahashi, S. et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J. Lipid Res. 57, 2130â2137 (2016).
Google ScholarÂ
Gardès, C. et al. Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlrâ/â mice versus hamsters [S]. J. Lipid Res. 54, 1283â1299 (2013).
Google ScholarÂ
Song, X. et al. Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor. J. Lipid Res. 54, 3030â3044 (2013).
Google ScholarÂ
Honda, A. et al. Increased bile acid concentration in liver tissue with cholesterol gallstone disease. J. Gastroenterol. 30, 61â66 (1995).
Google ScholarÂ
Gómez, C. et al. Development and validation of a highly sensitive LC-MS/MS method for the analysis of bile acids in serum, plasma, and liver tissue samples. Metabolites 10, 282 (2020).
Google ScholarÂ
James, S. C. et al. Concentrations of fecal bile acids in participants with functional gut disorders and healthy controls. Metabolites 11, 612 (2021).
Google ScholarÂ
Jäntti, S. E. et al. Quantitative profiling of bile acids in blood, adipose tissue, intestine, and gall bladder samples using ultra high performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 406, 7799â7815 (2014).
Google ScholarÂ
Straniero, S. et al. Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism. J. Lipid Res. 61, 480â491 (2020).
Google ScholarÂ
Zheng, W. et al. Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR. J. Biol. Chem. 293, 12535â12541 (2018).
Google ScholarÂ